Biocomposites (UK) Ltd, trading as Biocomposites


Keele Science Park,

Contact Details
Twitter: @Biocomposites1
LinkedIn: biocomposites-ltd

Winners Of

  • 2022 International Trade
  • 2022 Innovation

Biocomposites Ltd – a winner of two Queen’s Awards – is an international medical device company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue. Its team is 220-strong and it is based in Keele, UK with global operations across Europe, the US, Canada, China and India.

A world leader in the development of innovative calcium compounds for surgical use, its products include a number of world-firsts, and target a broad spectrum of infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry.

Innovation Award
Biocomposites’ innovative calcium compound devices range from bone grafts to matrices that can carry antibiotics to treat bacterial infection.

STIMULAN® is the only calcium matrix antibiotic carrier approved to treat bacterial infection in Canada and for use in bone and soft tissue in the EU, UK and Saudi Arabia. It is approved for mixing with the three most commonly used antibiotics – vancomycin, gentamicin and tobramycin – and can be placed directly into infected and non-infected sites.

Offering surgeons the flexibility to apply broad-spectrum ‘off the shelf’ antibiotics at concentrations that will support their patient specific treatment plans, STIMULAN dramatically improves patient outcomes and has redefined the standard of care.

genex® is an innovative, versatile synthetic bone graft that promotes regeneration of bone in osseous defects and is the first synthetic bone graft with a negatively charged surface chemistry to accelerate bone healing.

International Trade Award
Biocomposites’ products are sold in more than 40 countries and are used in over 120,000 procedures every year in thousands of hospitals around the world, including more than 200 hospitals in the UK and 2,200 hospitals in the US.

It is the only supplier providing calcium sulfate antibiotic carriers for use in bone and soft tissue to the UK’s NHS. Its overseas sales achieved outstanding continuous growth of more than 200% over the past six years, particularly in the United States, the Netherlands, China, Canada and India.

A proud achievement
Michael Harris, CEO of Biocomposites, said: “The Queen’s Awards are the most prestigious business awards in the UK and we are proud that Biocomposites has been honoured with two of them.

“It is very pleasing to see our relentless focus on research and development recognised with an innovation award for STIMULAN as well as recognition for our incredible growth in global markets. I would like to thank the entire team at Biocomposites, whose dedication to innovation and helping patients has made this achievement possible.”